STOCK TITAN
  1. Home
  2. Sec-filings
  3. CYTK
  4. [8-K] CYTOKINETICS INC Reports Material Event

EU approves Cytokinetics (NASDAQ: CYTK) MYQORZO for obstructive hypertrophic cardiomyopathy

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Cytokinetics reported that the European Commission has approved MYQORZO® (aficamten) tablets at 5 mg, 10 mg, 15 mg and 20 mg strengths. The drug is indicated for adult patients with symptomatic, obstructive hypertrophic cardiomyopathy classified as New York Heart Association class II–III. This approval allows Cytokinetics to offer a novel allosteric, reversible inhibitor of cardiac myosin motor activity as a treatment option for this specific heart condition across the European Union.

Positive

  • European Commission approval of MYQORZO: MYQORZO (aficamten) tablets at 5, 10, 15 and 20 mg were approved for symptomatic NYHA class II–III obstructive hypertrophic cardiomyopathy in adult patients, adding a new approved therapy for this condition in the European Union.

Negative

  • None.

Insights

European Commission approval for MYQORZO significantly advances Cytokinetics’ cardiomyopathy franchise.

The European Commission approved MYQORZO (aficamten) tablets (5–20 mg) for adult patients with symptomatic, obstructive hypertrophic cardiomyopathy in New York Heart Association class II–III. This converts development efforts into a commercial-stage asset in a major regulated market.

MYQORZO is described as an allosteric and reversible inhibitor of cardiac myosin motor activity, highlighting a targeted mechanism for treating this heart muscle disease. The labeled population focuses on symptomatic adults with obstructive disease, which narrows use to a clearly defined clinical group.

The approval opens the door to European launch execution, pricing negotiations, and future real-world evidence generation, though specifics are not detailed here. Subsequent company communications and filings will likely outline launch timing, commercialization partners, and any additional post-approval commitments.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Understanding 8-K Material Events →
false000106198300010619832026-02-172026-02-17

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 17, 2026

 

 

Cytokinetics, Incorporated

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-50633

94-3291317

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

350 Oyster Point Boulevard

 

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 624-3000

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value

 

CYTK

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 8.01 Other Events.

Cytokinetics, Incorporated today announced that the European Commission has approved MYQORZO® (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy in adult patients. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

CYTOKINETICS, INCORPORATED

 

 

 

 

Date:

February 17, 2026

By:

/s/ John O. Faurescu

 

 

 

John O. Faurescu
SVP, Deputy General Counsel & Secretary

 

Source: View Original Filing on SEC EDGAR

FAQ

What did Cytokinetics (CYTK) announce about MYQORZO in this 8-K?

Cytokinetics announced that the European Commission approved MYQORZO (aficamten) tablets for treating symptomatic obstructive hypertrophic cardiomyopathy in certain adults. The decision makes MYQORZO an approved therapy in the European Union, advancing the company’s cardiovascular portfolio into a commercial setting.

For which patients is MYQORZO now approved in the European Union?

MYQORZO is approved for adult patients with symptomatic obstructive hypertrophic cardiomyopathy in New York Heart Association class II–III. This targets individuals whose disease causes noticeable symptoms and functional limitations, but who are not yet in the most advanced NYHA class IV stage.

What dosage strengths of MYQORZO did the European Commission approve?

The European Commission approved MYQORZO tablets in 5 mg, 10 mg, 15 mg and 20 mg strengths. Multiple tablet strengths allow physicians to tailor dosing for individual patients within the approved indication, following applicable prescribing information and clinical judgment in the European Union.

What is the mechanism of action of MYQORZO (aficamten)?

MYQORZO (aficamten) is described as an allosteric and reversible inhibitor of cardiac myosin motor activity. By modulating cardiac myosin, it is designed to address abnormal heart muscle contraction associated with obstructive hypertrophic cardiomyopathy, within the specific patient population covered by the approval.

Does this Cytokinetics 8-K discuss financial results or earnings?

No, this 8-K focuses on a regulatory development: European Commission approval of MYQORZO for obstructive hypertrophic cardiomyopathy. It does not present revenue, earnings, or detailed financial metrics, concentrating instead on the new therapeutic approval and its clinical scope.

How does the European Commission approval affect Cytokinetics’ product portfolio?

The approval adds MYQORZO as an authorized treatment for obstructive hypertrophic cardiomyopathy in European adult patients with NYHA class II–III symptoms. This moves Cytokinetics beyond development into marketing a cardiomyopathy therapy in the European Union, broadening the company’s late-stage cardiovascular portfolio.

Filing Exhibits & Attachments

1 document

Other Documents